Evaluation of the drug-drug interactions management system for appropriate use of nirmatrelvir/ritonavir: a retrospective observational study

Table 4 Clinical outcomes of the included patients

Clinical outcomes	Total (n = 241)		NMV-r group (n = 126)		MOV group (n = 115)
Clinical outcomes	n	% [95%CI]	n	% [95%CI]	n	% [95%CI]
Patients requiring oxygen therapy within 30 days related to COVID-19	14	6.3 [3.5–10.4]	4	3.4 [0.9–8.5]	10	9.5 [4.7–16.8]
Unknown or no subjects^a	19		9		10
Patients requiring ventilatory support within 30 days	1	0.4 [0.1–2.4]	0	0.0 [0.0–3.0]	1	1.0 [0.02–5.2]
Unknown^b	15		5		10
30-day all-cause mortality	2	0.9 [0.1–3.1]	0	0.0 [0.0–3.0]	2	1.9 [0.2–6.5]
Unknown^b	10		3		7

CI confidence interval, COVID-19 the coronavirus disease 2019, MOV molnupiravir, NMV-r nirmatrelvir/ritonavir
^aPatients with unknown clinical outcomes or those who received oxygen therapy before initiating antivirals were excluded
^bPatients with unknown clinical outcomes were excluded

ISSN: 2055-0294